Protein kinase inhibitors

Abstract

A compound of formula (I), wherein R 3 , R 4 , G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.

1 - 18 . (canceled) 
     
     
         19 . A method for the treatment of cancer comprising administering an effective amount of a compound of formula (I) 
       
         
           
           
               
               
           
         
         wherein 
         is CH or N; 
         G is a group of formula 
       
       
         
           
           
               
               
           
         
         wherein ring A is a phenyl ring or a 5-12 membered heterocyclic ring, and 
         R 1  is H, C 1-7  alkyl, C 3-7  cycloalkyl, C 3-7  cycloalkyl C 1-7  alkyl, C 1-7  alkoxy, C 1-7  alkyl carbonyl, amino, hydroxy, hydroxy C 1-7  alkyl, C 1-7  alkylamino C 1-7  alkyl, phenyl C 1-7  alkoxy, —NHC(O)—R 21 , —R 12 —C(O)—R 13 , —SO 2 —R 14  or -E-R 6 , and 
         R 2  is H, halogen, C 1-7  alkyl or oxo; 
         ring B is a 5-12 membered carbocyclic or heterocyclic ring; 
         R 3  is H, halogen, C 1-7  alkyl, C 1-7  alkoxy, cyano or an optionally substituted 5-6 membered heterocyclic ring; 
         R 4  is H, halogen, C 1-7  alkyl or oxo; 
         M is —NHR 5 ; 
         R 5  is H, —C(O)R 7 , —SO 2 R 8 , —C(O)-D-R 9  or an optionally substituted 5-6 membered heterocyclic ring; 
         R 6  is an optionally substituted 5-6 membered heterocyclic ring; 
         R 7  is C 1-7  alkyl, C 2-7  alkenyl, C 3-7 cycloalkyl, C 1-7  alkoxy, C 1-7  alkoxy C 1-7  alkyl, carboxy C 1-7  alkyl, C 1-7  alkoxy carbonyl C 1-7  alkyl, C 1-7 alkylamino C 1-7  alkyl, —NH—R 10  or —NH—X 1 —R 11 ; 
         R 8  is C 1-7  alkyl, C 2-7  alkenyl, C 3-7  cycloalkyl, hydroxy C 1-7  alkyl, —NR 18 R 19 , —NH—X 2 —R 20 , phenyl or an optionally substituted 5-6 membered heterocyclic ring; 
         R 9  is phenyl or an optionally substituted 5-6 membered heterocyclic ring; 
         R 10  is C 1-7  alkyl or C 3-7  cycloalkyl; 
         R 11  is phenyl or an optionally substituted 5-6 membered heterocyclic ring; 
         R 12  and R 21  are C 1-7  alkyl; 
         R 13  is C 1-7  alkoxy, amino or hydroxy; 
         R 14  is C 1-7  alkyl or C 3-7  cycloalkyl; 
         R 18  and R 19  are, independently, H, C 1-7  alkyl or C 3-7  cycloalkyl; 
         R 20  is phenyl or an optionally substituted 5-6 membered heterocyclic ring; 
         E is a bond or a C 1-7  alkyl; 
         D is a bond or a C 1-7  alkyl; 
         X 1  and X 2  are, independently, a bond or C 1-7  alkyl; 
         or a pharmaceutically acceptable salt thereof to a patient in need thereof. 
       
     
     
         20 . The method according to  claim 19 , wherein the cancer is multiple myeloma. 
     
     
         21 . The method according to  claim 19 , wherein the cancer is gastric cancer. 
     
     
         22 . The method according to  claim 19 , wherein the cancer is endometrial cancer. 
     
     
         23 . The method according to  claim 19 , wherein the cancer is prostate cancer. 
     
     
         24 . The method according to  claim 19 , wherein the cancer is breast cancer.